Logo image of ISPR

ISPIRE TECHNOLOGY INC (ISPR) Stock Fundamental Analysis

NASDAQ:ISPR - Nasdaq - US46501C1009 - Common Stock - Currency: USD

2.94  -0.05 (-1.67%)

After market: 2.94 0 (0%)

Fundamental Rating

3

Taking everything into account, ISPR scores 3 out of 10 in our fundamental rating. ISPR was compared to 8 industry peers in the Tobacco industry. While ISPR seems to be doing ok healthwise, there are quite some concerns on its profitability. ISPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ISPR had negative earnings in the past year.
ISPR had a positive operating cash flow in the past year.
ISPR Yearly Net Income VS EBIT VS OCF VS FCFISPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of ISPR (-17.39%) is worse than 75.00% of its industry peers.
With a Return On Equity value of -94.76%, ISPR perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -17.39%
ROE -94.76%
ROIC N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISPR Yearly ROA, ROE, ROICISPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

Looking at the Gross Margin, with a value of 21.60%, ISPR is doing worse than 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of ISPR has grown nicely.
The Profit Margin and Operating Margin are not available for ISPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A
ISPR Yearly Profit, Operating, Gross MarginsISPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 5 -5 10 15

5

2. Health

2.1 Basic Checks

ISPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ISPR has been increased compared to 1 year ago.
ISPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISPR Yearly Shares OutstandingISPR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
ISPR Yearly Total Debt VS Total AssetsISPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that ISPR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.34, ISPR is in line with its industry, outperforming 50.00% of the companies in the same industry.
There is no outstanding debt for ISPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC8.98%
ISPR Yearly LT Debt VS Equity VS FCFISPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

ISPR has a Current Ratio of 1.06. This is a normal value and indicates that ISPR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.06, ISPR is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 0.98 indicates that ISPR may have some problems paying its short term obligations.
The Quick ratio of ISPR (0.98) is better than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.98
ISPR Yearly Current Assets VS Current LiabilitesISPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M 100M

6

3. Growth

3.1 Past

ISPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -178.48%.
ISPR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.10%.
Measured over the past years, ISPR shows a very strong growth in Revenue. The Revenue has been growing by 33.80% on average per year.
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)5.1%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%0.34%

3.2 Future

Based on estimates for the next years, ISPR will show a very strong growth in Earnings Per Share. The EPS will grow by 22.13% on average per year.
ISPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.30% yearly.
EPS Next Y-49.15%
EPS Next 2Y22.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.29%
Revenue Next 2Y20.3%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ISPR Yearly Revenue VS EstimatesISPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
ISPR Yearly EPS VS EstimatesISPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ISPR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISPR Price Earnings VS Forward Price EarningsISPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISPR Per share dataISPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as ISPR's earnings are expected to grow with 22.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.13%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ISPR!.
Industry RankSector Rank
Dividend Yield N/A

ISPIRE TECHNOLOGY INC

NASDAQ:ISPR (4/17/2025, 8:00:02 PM)

After market: 2.94 0 (0%)

2.94

-0.05 (-1.67%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)02-07 2025-02-07/amc
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners9.7%
Inst Owner Change-0.15%
Ins Owners4.81%
Ins Owner Change0.58%
Market Cap167.84M
Analysts82.86
Price Target9.18 (212.24%)
Short Float %4.35%
Short Ratio16.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-79.74%
Min EPS beat(2)-96.08%
Max EPS beat(2)-63.4%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.62%
Min Revenue beat(2)-25.34%
Max Revenue beat(2)6.1%
Revenue beat(4)2
Avg Revenue beat(4)-11.92%
Min Revenue beat(4)-35.33%
Max Revenue beat(4)6.9%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-140%
EPS NY rev (1m)-6.02%
EPS NY rev (3m)-69.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-31.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.13
P/FCF N/A
P/OCF 71.18
P/B 6.93
P/tB 7.59
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0.04
OCFY1.4%
SpS2.6
BVpS0.42
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.39%
ROE -94.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.6%
FCFM N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A
F-Score4
Asset Turnover1.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.49%
Cap/Sales 1.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.98
Altman-Z 1.34
F-Score4
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)1179.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-178.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-49.15%
EPS Next 2Y22.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.1%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%0.34%
Revenue Next Year6.29%
Revenue Next 2Y20.3%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-210.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-79.92%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-100.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-75.42%
OCF growth 3YN/A
OCF growth 5YN/A